# SOCS1

## Overview
The SOCS1 gene encodes the suppressor of cytokine signaling 1 protein, a critical regulator of cytokine signaling pathways, particularly the Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway. As a member of the SOCS family, SOCS1 functions primarily as a negative feedback regulator, modulating immune responses and maintaining cellular homeostasis. The SOCS1 protein is characterized by its Src Homology 2 (SH2) domain, kinase inhibitory region (KIR), and SOCS box motif, which collectively enable it to inhibit kinase activity and target proteins for ubiquitination and degradation. Through these mechanisms, SOCS1 plays a vital role in controlling immune cell proliferation and differentiation, preventing excessive inflammatory responses, and maintaining immune tolerance. Dysregulation of SOCS1, through mutations or epigenetic modifications, is implicated in various autoimmune diseases and cancers, highlighting its significance in both health and disease (Körholz2021One; Michniacki2022SOCS1; Yoshimura2007SOCS).

## Structure
The SOCS1 protein is characterized by several distinct structural features that contribute to its function as a suppressor of cytokine signaling. It contains a central Src Homology 2 (SH2) domain, which is crucial for binding to phosphorylated tyrosine motifs on target proteins. This domain includes an extended SH2 subdomain (ESS) that stabilizes the phosphotyrosine-binding loop, enhancing its binding specificity (Linossi2018Understanding; Ying2019SOCS1).

SOCS1 also possesses a kinase inhibitory region (KIR), a 12-residue motif that acts as a pseudosubstrate for Janus kinases (JAKs), effectively blocking their activity by occupying the substrate-binding groove (Liau2018The; La2022Adhoc). The KIR is located upstream of the SH2 domain and interacts with JAKs through a phosphotyrosine-independent interface (Linossi2018Understanding).

The C-terminal SOCS box motif of SOCS1 recruits an E3 ubiquitin ligase complex, facilitating the polyubiquitination and degradation of substrate proteins. This complex includes adapter proteins elongins B and C, Rbx2, and the scaffold protein Cullin5 (Ying2019SOCS1). The SOCS box contains two core interaction sites: the BC-box, which recruits elongins B and C, and the Cul-box, which mediates Cullin5 binding (Ying2019SOCS1).

SOCS1 lacks a functional PEST motif, which affects its stability and localization compared to other SOCS proteins (Linossi2018Understanding). The protein is subject to post-translational modifications, such as phosphorylation, which may influence its activity and interactions.

## Function
The SOCS1 gene encodes a protein that plays a critical role in regulating cytokine signaling pathways, particularly through the JAK/STAT pathway, which is essential for maintaining immune homeostasis in healthy human cells. SOCS1 functions as a negative regulator by inhibiting the phosphorylation of Janus kinases (JAKs) and non-receptor tyrosine kinase-2 (TYK2), as well as surface cytokine receptors, thereby modulating cell functions and preventing excessive inflammatory responses (Körholz2021One; Yoshimura2007SOCS).

SOCS1 acts as an E3 ubiquitin ligase, forming a complex with ElonginB/C to ubiquitinate target proteins for proteasomal degradation, influencing protein turnover and signaling cascades (Körholz2021One). It is involved in the regulation of multiple signaling pathways, including the FAK1-AKT-RPS6K pathway, where its haploinsufficiency leads to increased activity (Körholz2021One).

In the immune system, SOCS1 is crucial for modulating T-cell development and differentiation, particularly in the thymus, and for maintaining the balance between pro-inflammatory and anti-inflammatory signals. It prevents hyperactivation of immune responses by regulating TLR signaling and controlling T cell proliferation (Körholz2021One; Yoshimura2007SOCS). SOCS1 also plays a role in preventing the dysregulated proliferation of self-reactive T cells, which can lead to autoimmune conditions (Yoshimura2007SOCS).

## Clinical Significance
Mutations and alterations in the SOCS1 gene are linked to a variety of immune-related conditions and malignancies. Heterozygous loss-of-function mutations in SOCS1 are associated with early-onset autoimmune diseases, characterized by hyperactivation of lymphocytes and increased STAT activation in response to cytokines such as IFN-γ, IL-2, and IL-4 (Sobah2021SOCS; Hadjadj2020Earlyonset). SOCS1 haploinsufficiency can lead to enhanced interferon signaling, contributing to autoimmune and inflammatory conditions similar to systemic lupus erythematosus (Michniacki2022SOCS1).

In cancer, SOCS1 silencing through methylation or mutation is common in immune cell malignancies. In acute and chronic myeloid leukemia, SOCS1 methylation impairs its regulatory function on JAK2 activity, promoting STAT3 and STAT5 activation, which are crucial in leukemia development (Sobah2021SOCS). SOCS1 mutations are frequent in B cell malignancies, such as Hodgkin's lymphoma, where they are associated with shorter survival and hyperactivation of JAK2 and STAT6 (Sobah2021SOCS). Similar mutations are found in diffuse large B cell lymphoma and other related conditions, often leading to poor therapeutic responses (Sobah2021SOCS).

SOCS1 haploinsufficiency is also linked to immune dysregulation and multisystem inflammatory syndrome in children, with increased JAK activity and enhanced STAT1 phosphorylation (Lee2020Immune). This condition can manifest as severe enthesitis, bone marrow hypocellularity, and refractory thrombocytopenia, with JAK inhibition showing therapeutic promise (Michniacki2022SOCS1).

## Interactions
SOCS1 interacts with various proteins to regulate cytokine signaling pathways. It is a potent inhibitor of Janus kinases (JAKs), particularly JAK1, JAK2, and TYK2, but not JAK3. SOCS1 inhibits these kinases by binding to their catalytic domains, using its SH2 domain and kinase inhibitory region (KIR) to block substrate binding and prevent phosphorylation (Liau2018The). 

SOCS1 also interacts with the Elongin B and C proteins, forming a complex that stabilizes SOCS1 and facilitates its function. This interaction is crucial for SOCS1's stability, as demonstrated by experiments showing that SOCS1 levels remain stable when coexpressed with Elongins B and C (Kamura1998The). The SOCS box domain of SOCS1 is involved in recruiting E3 ubiquitin ligases, although it binds weakly to Cullin5 due to an atypical binding sequence (Liau2018The; Babon2009The).

In the context of type I interferon signaling, SOCS1 interacts with the tyrosine kinase Tyk2, associated with the interferon α receptor (IFNAR1). SOCS1 binds to Tyk2 through its SH2 and KIR domains, inhibiting Tyk2's kinase activity and reducing IFN signaling (Piganis2011Suppressor). This interaction also involves the inhibition of Lys-63-linked polyubiquitination of Tyk2, which is crucial for its activation (Piganis2011Suppressor).


## References


[1. (Yoshimura2007SOCS) Akihiko Yoshimura, Tetsuji Naka, and Masato Kubo. Socs proteins, cytokine signalling and immune regulation. Nature Reviews Immunology, 7(6):454–465, May 2007. URL: http://dx.doi.org/10.1038/nri2093, doi:10.1038/nri2093. This article has 1221 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/nri2093)

[2. (Linossi2018Understanding) Edmond M. Linossi, Dale J. Calleja, and Sandra E. Nicholson. Understanding socs protein specificity. Growth Factors, 36(3–4):104–117, July 2018. URL: http://dx.doi.org/10.1080/08977194.2018.1518324, doi:10.1080/08977194.2018.1518324. This article has 37 citations and is from a peer-reviewed journal.](https://doi.org/10.1080/08977194.2018.1518324)

[3. (Sobah2021SOCS) Mohamed Luban Sobah, Clifford Liongue, and Alister C. Ward. Socs proteins in immunity, inflammatory diseases, and immune-related cancer. Frontiers in Medicine, September 2021. URL: http://dx.doi.org/10.3389/fmed.2021.727987, doi:10.3389/fmed.2021.727987. This article has 82 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fmed.2021.727987)

[4. (La2022Adhoc) Sara La Manna, Sara Fortuna, Marilisa Leone, Flavia A. Mercurio, Ilaria Di Donato, Rosa Bellavita, Paolo Grieco, Francesco Merlino, and Daniela Marasco. Ad-hoc modifications of cyclic mimetics of socs1 protein: structural and functional insights. European Journal of Medicinal Chemistry, 243:114781, December 2022. URL: http://dx.doi.org/10.1016/j.ejmech.2022.114781, doi:10.1016/j.ejmech.2022.114781. This article has 6 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/j.ejmech.2022.114781)

[5. (Kamura1998The) Takumi Kamura, Shigeo Sato, Dewan Haque, Li Liu, William G. Kaelin, Ronald C. Conaway, and Joan Weliky Conaway. The elongin bc complex interacts with the conserved socs-box motif present in members of the socs, ras, wd-40 repeat, and ankyrin repeat families. Genes &amp; Development, 12(24):3872–3881, December 1998. URL: http://dx.doi.org/10.1101/gad.12.24.3872, doi:10.1101/gad.12.24.3872. This article has 478 citations.](https://doi.org/10.1101/gad.12.24.3872)

[6. (Babon2009The) Jeffrey J. Babon, Jennifer K. Sabo, Jian-Guo Zhang, Nicos A. Nicola, and Raymond S. Norton. The socs box encodes a hierarchy of affinities for cullin5: implications for ubiquitin ligase formation and cytokine signalling suppression. Journal of Molecular Biology, 387(1):162–174, March 2009. URL: http://dx.doi.org/10.1016/j.jmb.2009.01.024, doi:10.1016/j.jmb.2009.01.024. This article has 104 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/j.jmb.2009.01.024)

[7. (Piganis2011Suppressor) Rebecca A.R. Piganis, Nicole A. De Weerd, Jodee A. Gould, Christian W. Schindler, Ashley Mansell, Sandra E. Nicholson, and Paul J. Hertzog. Suppressor of cytokine signaling (socs) 1 inhibits type i interferon (ifn) signaling via the interferon α receptor (ifnar1)-associated tyrosine kinase tyk2. Journal of Biological Chemistry, 286(39):33811–33818, September 2011. URL: http://dx.doi.org/10.1074/jbc.m111.270207, doi:10.1074/jbc.m111.270207. This article has 129 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.m111.270207)

[8. (Michniacki2022SOCS1) Thomas F. Michniacki, Kelly Walkovich, Lauren DeMeyer, Nadine Saad, Mark Hannibal, Matthew L. Basiaga, Kelly K. Horst, Smriti Mohan, Liang Chen, Kailey Brodeur, Yan Du, David Frame, Sandra Ngo, Jillian Simoneau, Noah Brown, and Pui Y. Lee. Socs1 haploinsufficiency presenting as severe enthesitis, bone marrow hypocellularity, and refractory thrombocytopenia in a pediatric patient with subsequent response to jak inhibition. Journal of Clinical Immunology, 42(8):1766–1777, August 2022. URL: http://dx.doi.org/10.1007/s10875-022-01346-x, doi:10.1007/s10875-022-01346-x. This article has 16 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1007/s10875-022-01346-x)

[9. (Liau2018The) Nicholas P. D. Liau, Artem Laktyushin, Isabelle S. Lucet, James M. Murphy, Shenggen Yao, Eden Whitlock, Kimberley Callaghan, Nicos A. Nicola, Nadia J. Kershaw, and Jeffrey J. Babon. The molecular basis of jak/stat inhibition by socs1. Nature Communications, April 2018. URL: http://dx.doi.org/10.1038/s41467-018-04013-1, doi:10.1038/s41467-018-04013-1. This article has 289 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/s41467-018-04013-1)

[10. (Hadjadj2020Earlyonset) Jérôme Hadjadj, Carla Noemi Castro, Maud Tusseau, Marie-Claude Stolzenberg, Fabienne Mazerolles, Nathalie Aladjidi, Martin Armstrong, Houman Ashrafian, Ioana Cutcutache, Georg Ebetsberger-Dachs, Katherine S. Elliott, Isabelle Durieu, Nicole Fabien, Mathieu Fusaro, Maximilian Heeg, Yohan Schmitt, Marc Bras, Julian C. Knight, Jean-Christophe Lega, Gaetan Lesca, Anne-Laure Mathieu, Marion Moreews, Baptiste Moreira, Audrey Nosbaum, Matthew Page, Cécile Picard, T. Ronan Leahy, Isabelle Rouvet, Ethel Ryan, Damien Sanlaville, Klaus Schwarz, Andrew Skelton, Jean-Francois Viallard, Sebastien Viel, Marine Villard, Isabelle Callebaut, Capucine Picard, Thierry Walzer, Stephan Ehl, Alain Fischer, Bénédicte Neven, Alexandre Belot, and Frédéric Rieux-Laucat. Early-onset autoimmunity associated with socs1 haploinsufficiency. Nature Communications, October 2020. URL: http://dx.doi.org/10.1038/s41467-020-18925-4, doi:10.1038/s41467-020-18925-4. This article has 93 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/s41467-020-18925-4)

[11. (Körholz2021One) Julia Körholz, Anastasia Gabrielyan, John M. Sowerby, Felix Boschann, Lan-Sun Chen, Diana Paul, David Brandt, Janina Kleymann, Martin Kolditz, Nicole Toepfner, Ralf Knöfler, Eva-Maria Jacobsen, Christine Wolf, Karsten Conrad, Nadja Röber, Min Ae Lee-Kirsch, Kenneth G. C. Smith, Stefan Mundlos, Reinhard Berner, Alexander H. Dalpke, Catharina Schuetz, and William Rae. One gene, many facets: multiple immune pathway dysregulation in socs1 haploinsufficiency. Frontiers in Immunology, August 2021. URL: http://dx.doi.org/10.3389/fimmu.2021.680334, doi:10.3389/fimmu.2021.680334. This article has 16 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fimmu.2021.680334)

[12. (Ying2019SOCS1) Jie Ying, Xiaoyan Qiu, Yu Lu, and Miaomiao Zhang. Socs1 and its potential clinical role in tumor. Pathology &amp; Oncology Research, 25(4):1295–1301, February 2019. URL: http://dx.doi.org/10.1007/s12253-019-00612-5, doi:10.1007/s12253-019-00612-5. This article has 26 citations.](https://doi.org/10.1007/s12253-019-00612-5)

[13. (Lee2020Immune) Pui Y. Lee, Craig D. Platt, Sabrina Weeks, Rachael F. Grace, George Maher, Kasey Gauthier, Sridevi Devana, Sally Vitali, Adrienne G. Randolph, Douglas R. McDonald, Raif S. Geha, and Janet Chou. Immune dysregulation and multisystem inflammatory syndrome in children (mis-c) in individuals with haploinsufficiency of socs1. Journal of Allergy and Clinical Immunology, 146(5):1194-1200.e1, November 2020. URL: http://dx.doi.org/10.1016/j.jaci.2020.07.033, doi:10.1016/j.jaci.2020.07.033. This article has 103 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1016/j.jaci.2020.07.033)